Evaluating and Optimizing Health System Specialty Pharmacy Operating Models with Fairview Pharmacy Solutions | NASP Specialty Pharmacy Podcast
- 32m
- Transcript
Summary
Written by a model from the transcript; not yet reviewed.
This episode explores how health systems evaluate and optimize their specialty pharmacy operating models, moving beyond the initial build phase to maximize value, capture rates, and patient outcomes. The guest, Mel Nelson from Fairview Pharmacy Solutions, explains how early reliance on accelerators helped rapidly expand health system specialty pharmacies over the past decade, with ASHP data showing growth from 8 percent in 2015 to over 25 percent by 2019, and nearly 300 health system specialty pharmacies identified recently. The discussion focuses on why mature systems must now assess whether their current models—particularly percentage-based fee structures and vendor dependencies—still align with their strategic goals, patient capture needs, and financial performance. The conversation provides a structured framework for health system leaders to evaluate five key areas: strategy, capabilities, market access and capture, financial ROI, and patient experience, while detailing when to maintain partnerships, when to insource, and how to execute a complex operational transition safely.
- Conduct a strategic review of your specialty pharmacy operating model by evaluating five core areas: strategy, capabilities, access, financial performance, and patient experience. 10:57
- Examine whether your economic model still makes sense as prescription volume and revenue scale into hundreds of millions of dollars. 19:45
- Model both the risks and costs of transitioning operations versus the hidden risks and missed opportunities of keeping the status quo. 24:46
- Begin evaluating your operating model and transition strategy at least two years before your current vendor or accelerator agreement approaches renewal. 26:31
Chapters
- 0:05Podcast Introduction and Host Overview
The episode opens with the podcast network’s introduction and the hosts set the stage for a discussion on specialty pharmacy operating models.
- 1:31Meet Mel Nelson and Fairview Pharmacy Solutions
Sheila Arkat introduces Mel Nelson, CEO of Fairview Pharmacy Solutions, outlining her background and role in specialty pharmacy consulting.
- 3:11Evolution of the Specialty Pharmacy Landscape
Mel describes how specialty pharmacy has grown from a niche service to a strategic component of health systems, citing ASHP data and market expansion.
- 6:05Three Pillars of Modern Specialty Pharmacy
The discussion highlights clinical scope expansion, strategic integration, and optimization of existing programs as key shifts in the industry.
- 10:57Assessing Current Operating Models
Mel outlines five critical areas—strategy, capabilities, access, financial performance, and patient care—to evaluate when considering a model shift.
- 15:46Benefits of Staying with an Accelerator
Mel explains scenarios where continuing with an accelerator remains advantageous, emphasizing expertise, scale, and rapid market changes.
- 22:49Risks of Changing Operating Models
The conversation covers patient care continuity, financial implications, and the importance of deliberate transition planning to mitigate risks.
- 25:54When to Reevaluate and Potential Triggers
The hosts discuss practical triggers for reassessment, such as volume growth, new therapeutic areas, leadership changes, and contract renewals.
- 27:08Fairview Pharmacy Solutions’ Transition Support
Mel details the comprehensive support Fairview offers—from assessment to execution—to help health systems transition or optimize their specialty pharmacy operations.
Highlights
- 3:33
Rapid Growth of Health System Specialty Pharmaciesdata
The guest highlights ASHP data showing that health system specialty pharmacies grew from 8 percent in 2015 to over 25 percent in 2019, reflecting a threefold increase driven largely by accelerator organizations.
- 4:21
Shift From Building to Optimizing Programsinsight
The discussion outlines how the specialty pharmacy market has matured, shifting from simply establishing new programs to asking sophisticated questions about prescription capture, payer restrictions, and clinical integration.
- 4:33
High Volume of Mature Operationsdata
Citing recent ASHP survey data, the guest notes that nearly 300 health system specialty pharmacies were identified, with 71 percent of respondents having operated for more than seven years.
- 12:34
Evaluating Financial Performance Beyond Feesstrategy
The guest explains that leaders should look past simple partnership costs and instead evaluate the full return on investment, comparing accelerator expenses against the fully loaded cost of bringing staff and technology in-house.
- 16:00
Reasons to Retain Accelerator Partnershipsinsight
The guest explains that continuing with an accelerator can still be the best choice when an organization lacks internal scale, leadership infrastructure, or specialized talent to manage complex payer strategies and accreditations.
- 19:10
Reassessing Economics at Scaleinsight
The guest points out that while paying a percentage of margin to an accelerator makes sense for a startup, a mature pharmacy generating hundreds of millions in revenue faces a vastly different economic burden that warrants re-evaluation.
- 24:14
Managing the Risk of Status Quoinsight
The guest argues that leaders often view the status quo as low risk, but failing to change when a health system is growing rapidly can result in substantial missed opportunities and misaligned capabilities.
- 27:28
Executing Complex Operational Transitionsstrategy
The guest describes how transitioning away from an accelerator requires building a complete specialty pharmacy business infrastructure—including staffing models, software platforms, and workflows—while maintaining uninterrupted patient care.
Quotes
“specialty meds are now accounting for more than half of the US pharmaceutical spend.”
Unnamed speaker · 5:15 “you are listening to the global network of podcasters dedicated to the pharmacy profession.”
Unnamed speaker · 0:05 “I think specialty pharmacy has matured, and the questions that health systems are asking have matured along with it.”
Unnamed speaker · 8:19
Sponsored segments
- NASP 32:15–32:39
About this episode
In this episode, Sheila Arquette, President & CEO of NASP, speaks with Mel Nelson, PharmD, CSP, Vice President, Specialty Consulting Services of Fairview Pharmacy Solutions. They discuss how the health system specialty pharmacy landscape has matured over the past decade, and why many organizations are now asking a new question: is our current operating model still the right one for where we want to go next? Mel walks through the key strategic, clinical, and financial factors health systems should evaluate when reassessing accelerator partnerships, the circumstances that might prompt a move toward insourcing capabilities, and how to protect patient care continuity through any transition. The conversation also covers how Fairview Pharmacy Solutions partners with health systems to design and execute successful transitions while building sustainable, long-term internal capability.
Transcript
5,630 words · 5 speakers
Topics
- ASHP
- Pharmacy Podcast Network
- Fairview Pharmacy Solutions
- National Association of Specialty Pharmacy
- Fairview Pharmacy Services
- IQVIA
- FDA
Page updated · transcript and summary are machine-generated